Novel Agents for the Management of Relapsed Multiple Myeloma – European Medical Journal
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. MM accounts…
Related Articles
Hema Now: Episode 21: Global Perspectives on Myeloma
Claudio Cerchione discusses multiple myeloma, MRD, CAR-T therapy, and key takeaways from EHA and ASCO in this insightful hema now episode.
Hema Now: Episode 19: Insights and Innovations in B Cell Disorders
Lydia Scarfò discusses types of leukaemia, current treatment approaches, recent advances, and future possibilities.
Subscribe to our email newsletter
Subscribe to receive our free quarterly newsletters, journal publication alerts, and other relevant content.
Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies
Rafael Fonseca, Consultant, Division of Hematology/Oncology, Mayo Clinic, uncovers the biology, diagnosis & management of multiple myeloma.
COMy 2025: Diagnosis Delays in Amyloid Light-Chain Amyloidosis
A new study presented at COMy 2025 reveals that patients with amyloid light-chain amyloidosis still face significant delays in diagnosis, often leading to severe cardiac…
COMy 2025: Senescence Biomarkers Predict Frailty and Survival in Myeloma
New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with frailty and overall survival in newly diagnosed multiple myeloma.
Subscribe to our email newsletter
Subscribe to receive our free quarterly newsletters, journal publication alerts, and other relevant content.
Blood Test Offers Breakthrough in Heart Disease Treatment
A groundbreaking study has introduced a novel, image-based blood test that could significantly enhance the way doctors manage and personalise treatment for coronary artery disease…
COMy 2025: Infection Risk High with Bispecific Antibodies in Myeloma
New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma receiving bispecific antibodies targeting CD3/BCMA and…
Hema Now: Episode 17: What Drives Change in Leukaemia Cells?
Paolo Gallipoli, Clinical Reader, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London joins the podcast